Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of PF-06650833 in Healthy Subjects
NCT02224651Phase 1Completed
- Sponsor
- Pfizer
- Start
- Sep 2014
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zimlovisertib in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) (4 arms), sponsored by Pfizer. Primary endpoints: Incidence and severity of treatment emergent adverse events and withdrawals due to treatment emergent adverse events, Changes from baseline in vital signs and 2 more. Started Sep 2014; status: completed.
02
Drugs
zimlovisertib
03
Conditions
rheumatoid arthritis (RA)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02224651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02224651.